Register Login

BridgeBio Pharma (BBIO)

  • Event
  • May 18, 2022, 20:02 UTC

(10% Negative) BridgeBio Pharma, Inc. (BBIO) Announces Delay in million Trials for rare pediatric diseases Due to Pandemic-Related Challenges, Regulatory Process, Manufacturing Considerations

Full text
Register to leave comments
  • News bot Oct. 1, 2025, 9:13 p.m.

    📋 BridgeBio Pharma, Inc. (BBIO) - Clinical Trial Update

    Filing Date: 2022-05-18

    Accepted: 2022-05-18 16:02:03

    Event Type: Clinical Trial Update

    Event Details:

    BridgeBio Pharma (BBIO) Announces Clinical Trial Update BridgeBio Pharma (BBIO) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: million, voucher
    • Diseases/Conditions: rare pediatric diseases, $110 million
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Pandemic-Related Challenges, Regulatory Process, Regulatory Timeline
    • Collaboration: PRV
      • targeting genetic diseases and cancers,” said Brian Stephenson, Ph.D., CFA, BridgeBio’s Chief Financial Officer. “We believe this deal, coupled with our amended loan agreement, offers us the opportunity to read out more data within the duration of our debt and advance meaningful medicines to patients in need in the years to come.” About BridgeBio Pharma, Inc. BridgeBio Pharma, Inc. (BridgeBio) is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015
      • targeting genetic diseases and cancers and provide the Company the opportunity to read out more data within the duration of its debt and advance meaningful medicines to patients in need in the years to come, and reflect the Company’s current views about its plans, intentions, expectations and strategies, which are based on the information currently available to the Company and on assumptions the Company has made. Although the Company believes that its plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, it can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, the Company’s anticipated cash runway and its ability to advance the Company’s pipeline programs, the success of the Company’s long-term strategy of creating non-dilutive financing pathways, the success of portfolio readouts in unlocking additional capital under the credit facility, potential volatility in the Company’s share price, potential adverse impacts due to the global COVID-19 pandemic such as delays in regulatory review, manufacturing and supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy, as well as those risks set forth in the Risk Factors section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2021

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: BridgeBio Pharma
    • CIK: 0001743881
    • Ticker Symbol: BBIO
    • Period End Date: 2022-05-12
    • Document Type: 8-K

Search

News categories